| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:2465.)
© 2002 American Heart Association, Inc.
Brief Rapid Communications |
From the Center for Research in Cardiovascular Interventions, Stanford University Medical Center, Stanford, Calif (Y.M., T.L., Y.H., P.G.Y., P.J.F.); Washington Hospital Center, Washington, DC (R.W.); Cardiovascular Research Foundation, New York, NY (A.J.L., G.S.M.); and Highlands Consulting Inc, San Jose, Calif (H.N.B.).
Correspondence to Peter J. Fitzgerald, MD, PhD, Center for Research in Cardiovascular Interventions, Stanford University Medical Center, 300 Pasteur Dr, H3554, Stanford, CA 94305-5637. E-mail ivus{at}crci.stanford.edu
Background Re-stenting of in-stent restenosis (ISR) improves acute angiographic results.
Methods and Results Volumetric intravascular ultrasound analysis was performed in 70 ISR lesions that received either placebo (n=36) or 192Ir radiation (n=34). ISR lesions treated by re-stenting were divided into 3 groups: old stent not re-stented (A), old/new stent overlap (B), and new stent only (C). ISR lesions treated without re-stenting were categorized as D. In placebo patients, postintervention lumen volume index (LVI) was significantly greater in re-stented segments B and C than in nonre-stented segment A (P<0.05).At follow-up, however, LVI was similar in all 4 segments secondary to the increased intimal hyperplasia (IH) reaccumulation within the re-stented segments. In patients treated with 192Ir radiation, LVI was maintained from baseline to follow-up only in nonre-stented segments A and D. Conversely, there was a significant decrease in LVI in re-stented segments B and C (P<0.05). Qualitatively, 79% of patients in the irradiated group had stent struts with undetectable neointimal versus only 27% in the placebo group (P<0.001). Coefficient of variation of IH reaccumulation was greater in re-stented segments of 192Ir patients (B=57.3% and C=58.9%) than in re-stented segments in placebo patients (B=27.3% and C 26.8%) and nonre-stented segments in irradiated patients.
Conclusions Additional lumen gain from re-stenting ISR lesions is counteracted by exaggerated neointimal proliferation in placebo patients. Maximum effectiveness and safety of radiation can be achieved for ISR lesions when treated without re-stenting. Thus, regardless of supplementary intravascular brachytherapy, repeat stenting strategies provided little long-term advantage.
Key Words: restenosis radioisotopes stents coronary disease
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |